Comparative analysis of antibody production by mRNA 1273, AZD 1222 and BBIBP-CorV on elderly people suffering from different co-morbidity in Bangladesh

  1. Ashraful Hoque
  2. Md Marufur Rahman
  3. Shahnewaz Parvez
  4. Hossain Imam
  5. Nurun Nahar
  6. Forhad Uddin Hasan Chowdhury

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Background

As the pandemic spread so quickly all over the world, the scientist did not get the right time to cover all age group populations for a vaccine trial. The elderly population is usually vulnerable for COVID-19 which was proven by different research work and focus was to save this group of people was the prime concern for every country of the world. Though vaccines that got emergency use authorization have proven their efficacy which one is better for elderly people suffering from different co-morbid conditions is still not established. In this study, we want to evaluate the antibody production by mRNA 1273, AZD 1222, and BBIBP-CorV in elderly people with different comorbidity.

Method

We include 40 people in each group who have at least one comorbid condition and the total sample size was 120. The sample was taken from them before vaccination and 14 days after the second dose. Adverse event following immunization was recorded if any. Antibody measurement was done by ELISA method by using DiaSino SARS-CoV-2 S1 RBD IgG Quant.

Result

Among 120 participants with an equal number of participants in each of the vaccine groups all of them were aged between 60-72 years, of whom 65% were males and 35 % were females. Anti S1 RBD IgG was detected among all the participants from each vaccine group after 14 days of taking their 2nd dose. A non-parametric multiple comparison test (Kruskal-Wallis test) of Anti S1 RBD IgG levels among three vaccine groups revealed significant differences (P-value <0.05) between groups. The IgG level was almost twice in the mRNA-1273 group (mean 577.1± 44.33 AU/ml) compared to AZD1222(mean 308.5 ±37.91 AU/ml) and BBIBP-CorV group.

Conclusion

From this small sample size, we predicate that mRNA 1273 produce much higher anti-S1 RBD IgG than the other two vaccines. Every vaccine is safe and effective whose is approved by WHO. Calculative use of the vaccine may produce an outcome for the future as we are still way behind in the proper amount of vaccine production.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2021.11.15.21266338: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The study protocol was reviewed and approved by the Institutional Review Committee of the Sheikh Hasina National Institute of Burnand Plastic Surgery, Dhaka
    Consent: Informed written consent was taken from each participant.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Antibodies to the RBD of the S1 subunit of the viral spike protein (IgG) were performed from the plasma samples using a commercially available Anti-SARS-CoV-2 ELISA kit(DiaSino
    viral spike protein (IgG
    suggested: None
    Anti-SARS-CoV-2 ELISA
    suggested: None
    Software and Algorithms
    SentencesResources
    The analysis was performed in Graphpad Prism 9.0.
    Graphpad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Limitations and Future Suggestions: This small sample size cannot produce generalizability. Therefore, subsequent clinical studies with larger sample sizes with different age group should be enclosed to confirm our findings. Moreover, only antibody response could not evaluate the efficacy of any vaccine, cellular response should be evaluated.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2021.11.15.21266338v1 on medRxiv